Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) was the recipient of unusually large options trading on Thursday. Traders ...

The market in the United States has shown a flat performance over the last week but has risen by 22% over the past year, with earnings forecasted to grow by 15% annually. In this context, identifying ...

Biotechnology is a high-risk, high-reward landscape where innovation determines success. Yet, occasionally, a small player ...

Lipella Pharmaceuticals LIPO shares increased by 158.9% to $6.68 during Thursday's pre-market session. The market value of their outstanding shares is at $8.0 million. MBX Biosciences MBX stock moved ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Invivyd (IVVD) announced a strategic partnership with professional football coach Jim Harbaugh to raise awareness about the ongoing short and ...

Proud to partner with a company driven to provide options for COVID-19, Coach Harbaugh encourages Americans, especially the immunocompromised, to learn more about the short and potential long-term ...

Palantir reported fourth-quarter revenue of $827.52 million, beating the consensus estimate of $775.91 million. The company reported fourth-quarter adjusted earnings of 14 cents per share, beating ...

Invivyd, Inc. is a microcap biotech company focusing on antibody-based treatments for infectious diseases like COVID-19.

H.C. Wainwright reaffirmed its Buy rating and $10.00 price target for Invivyd Inc. (NASDAQ:IVVD), following a series of positive developments for the biotechnology company. The stock, currently ...